ESMO Breast 2023 | Phase Ib data CAPItello-292: capivasertib + palbociclib + fulvestrant in HR+/HER2- breast cancer

Patrick Neven, MD, PhD, UZ Leuven, Leuven, Belgium, provides an overview of Phase Ib results from the CAPItello-292 trial (NCT04862663, which evaluated the safety and efficacy of capivasertib, palbociclib, and fulvestrant vs placebo + palbociclib + fulvestrant in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer (ABC) who progressed on prior endocrine therapy and CDK4/6 inhibitors. The combination was found to be tolerable, and the recommended Phase III dose was identified as C400+P125+F500. The most common adverse events were diarrhea, neutropenia, fatigue, and nausea. No new safety risks or clinically relevant drug-drug interactions were identified. Preliminary efficacy and ctDNA data will be presented in the future. This interview took place at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.